Business Wire

UVLRX-THERAPEUTICS

Del

Pro-Aging Congress Highlights UVLrx™ Therapy’s Ability to Reduce Inflammation, the Leading Cause of Accelerated Aging

UVLrx Therapeutics ™ is pleased to present its intravenous light treatment system at the 5th Annual Pro-Aging Europe Congress , a four-day event highlighting medical therapies that reduce, slow down and even reverse the aging process. Beginning on November 19th , this year’s Congress will attract hundreds of the world’s leading anti-aging and aesthetics physicians.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151110007124/en/

Following the company’s recent CE Mark clearance for the UVLrx Station™ Model UVL1500, UVLrx Therapeutics™ will highlight the clinically-proven benefits of light wavelengths utilized by the UVLrx Treatment System. The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical issues. Using the company’s patent-pending Dry Light Adapter™ and a standard IV catheter, the device treats blood intravenously, thus eliminating the need for removal of blood from the body.

Among UVLrx Therapeutics Model UVL1500’s eight indications for use in the EU, the UVLrx™ Treatment System significantly reduces inflammation, the root cause of accelerated aging. It also significantly reduces pain and accelerates post surgical healing, two critical factors associated with many aesthetic procedures.

“We are excited to share our technology at the Congress this year and demonstrate in person how we can contribute to patient care within the field of aesthetics and aging,” says Michael Harter, CEO and president of UVLrx™. “By exhibiting at this event, under the supervision of Dr. Thierry Hertoghe , we have the opportunity to treat the world’s leading anti-aging physicians, which will help them understand firsthand UVLrx’s potential within this growing medical field.”

Ultraviolet Blood Irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion in drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.

To learn more, please visit http://uvlrx.com/ and http://bit.ly/1RLN2zb . Be sure to attend UVLrx’s Therapeutic Workshop at the Pro-Aging Congress featuring Chief Scientist Ryan Maloney on Friday, November 20th from 7:00 p.m. to 9:30 p.m.

About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to evidence-based medicine in the field of light therapy and offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical issues. In addition to two Nobel Prizes and NASA-backed research, hundreds of international clinical trials have verified the health benefits of UV and other wavelengths of light utilized in the UVLrx™ Treatment System. For more information, please visit www.uvlrx.com .

Contact:

Press:
Crier Communications
JP Lincoln, 310-274-1072 ext. 201
jp@crierpr.com
or
Business:
UVLrx Therapeutics
Rowland Hanson
Rowland@UVLrx.com

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com